NEW YORK ( TheStreet) -- Shares of Google ( GOOG) jumped in late trades on Thursday after the Internet search giant trounced Wall Street's earnings expectations for its third-quarter results.

"We had a great quarter," said Larry Page, CEO of Google, in a statement. "Revenue was up 33% year on year and our quarterly revenue was just short of $10 billion. Google+ is now open to everyone and we just passed the 40 million user mark. People are flocking into Google+ at an incredible rate and we are just getting started!"

The company reported non-GAAP earnings of $3.18 billion, or $9.72 a share, for the three months ended in September. Revenue totaled $9.72 billion. Excluding traffic acquisition costs of $2.21 billion, revenue came in at $7.51 billion. The average estimate of analysts polled by Thomson Reuters was for earnings of $8.74 a share for the quarter on revenue of $7.22 billion.

The stock was last quoted at $594.50, up 6.4%, on volume of 1.31 million, according to Nasdaq.com. Based on a regular session close at $558.99, the shares were down roughly 7.7% so far in 2011, although they've seen a healthy bounce since plumbing a 52-week low of $473.02 on June 24.

Google reported increases in both paid clicks and cost-per-click on year-over-year basis but did see a decline of 5% in cost-per-click on a sequential basis.

Depomed

The big loser after Thursday's closing bell was Depomed ( DEPO), which disappointed with the clinical results of a late-stage trial of Serada, its proposed drug to treat menopausal hot flashes.

The shares plunged 27% to $4.60 in extended trading with volume running above 405,000, according to Nasdaq.com.

Depomed said efficacy data from the phase III trial of Serada was "positive and statistically significant for three of the four pre-specified primary endpoints of frequency and severity at four and 12 weeks" and that data for key secondary endpoints at 24 weeks didn't achieve "statistical significance."

The company said the safety data found the tablets were well-tolerated and that it plans to discuss "possible pathways" for a new drug application with the Food and Drug Administration.

""We believe the data are sufficient to warrant discussion with the agency," said Jim Schoeneck, Depomed's president and CEO, in a statement. "We continue to believe Serada can offer clinical benefit as a non-hormonal treatment option for women suffering from menopausal hot flashes."

Also moving in late action was National CineMedia ( NCMI), which was down 23% to $11.32 on volume of around 30,000 after the company lowered its outlook for the fourth quarter and full year, citing weak advertising spending.

The Centennial, Colo.-based theater operator now sees revenue of $425 million to $435 million for 2011, down from a prior projection of $460 million to $470 million.

-- Written by Michael Baron in New York.

>To contact the writer of this article, click here: Michael Baron.

>To submit a news tip, send an email to: tips@thestreet.com
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

If you liked this article you might like

Alphabet Is the Best Tech Stock to Own After the Correction

Alphabet Is the Best Tech Stock to Own After the Correction

Why I Like Amazon, Apple and These Other Stocks for February

Why I Like Amazon, Apple and These Other Stocks for February

The Best Jobs in America

The Best Jobs in America

2018 Super Bowl Ad: Kraft Attempts to Make 'Family' a Verb

2018 Super Bowl Ad: Kraft Attempts to Make 'Family' a Verb

How to Trade Apple Stock Ahead of Earnings

How to Trade Apple Stock Ahead of Earnings